Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Michael Teiger

Pulmonary Disease West Hartford, CT Medical Doctor

NPI 1245343672 CMS profile 10605

345 N Main St, First Flr, West Hartford, CT 06117

Open in the dashboard

General payments

$7,065

345 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Michael Teiger of West Hartford, CT is reported in the CMS Open Payments database as having received $7,065 across 345 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $80 1
2022 General $2,538 128
2021 General $1,849 87
2020 General $740 41
2019 General $1,858 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Teiger
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Teiger were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Teiger Pulmonary Disease median Middle half National median
2019 $1,858 $377 $109–$1,340 $163
2020 $740 $230 $56–$907 $114
2021 $1,849 $269 $68–$1,072 $132
2022 $2,538 $390 $100–$1,457 $149
2023 $80 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $2,804 120 payments
  2. GlaxoSmithKline, LLC. $2,224 127 payments
  3. Mylan Specialty L.P. $484 18 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $337 17 payments
  5. Genzyme Corporation $305 18 payments
  6. Regeneron Healthcare Solutions, Inc. $273 13 payments
  7. Mallinckrodt Hospital Products Inc. $137 4 payments
  8. Janssen Pharmaceuticals, Inc $127 7 payments
  9. Covis Pharma B.V. $92 4 payments
  10. Amgen Inc. $63 4 payments
  11. Other $222 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,965 344 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2023
  1. FASENRA Respiratory $865 33 payments
  2. TRELEGY ELLIPTA $824 66 payments
  3. BREZTRI $717 24 payments
  4. FASENRA Respiratory $709 25 payments
  5. NUCALA Respiratory $575 21 payments
  6. TEZSPIRE $561 23 payments
  7. NUCALA Immunology $525 22 payments
  8. YUPELRI $414 15 payments
  9. SYMBICORT $318 12 payments
  10. DUPIXENT $273 13 payments
  11. Other $1,913 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

345 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record